Tuberculosis has been shown to make immune genes inaccessible and slows immune response The
purpose of this research is to see if if azacitidine is safe and can return the ability of
the body to resist tuberculosis (TB), a contagious infection that attacks the lungs.
Individuals with tuberculosis are being asked to participate. Some will receive a drug to
restore a host immunity while others can choose to receive standard of care. All patients
will continue to receive standard of care tuberculosis therapy regardless of whether they
chose to participate in the study.
This study is a Phase Ib/IIa single-institution, open-label, non-randomized clinical trial of
sub-cutaneous azacitidine in pulmonary TB patients during the continuation phase of ATT.